Milwaukee, Wisconsin
Phase 3 cancer trials in Milwaukee, WI
49 Phase 3 cancer studies are recruiting participants at sites in Milwaukee as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Milwaukee at a glance
- 49 studies are recruiting at a site in Milwaukee.
- By phase: Phase 2/3 (6), Phase 3 (43).
- By sponsor: university, hospital or other (22), industry (20), government (7).
- By research area: Lung Cancer (13), Breast Cancer (12), Lymphoma (9), Prostate Cancer (9), Pancreatic Cancer (5), Melanoma (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Milwaukee
Basic details from each study's public record (the 30 most recently updated of 49). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
- Registry record
- NCT06058377 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
- Registry record
- NCT06748222 · updated
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07173751 · updated
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07492641 · updated
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Aurora St Luke's Medical Center
- Registry record
- NCT07062965 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.
Lung cancer studies recruiting in Milwaukee
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07388524 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
- Registry record
- NCT06096844 · updated
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Aurora St. Luke's Medical Center
- Registry record
- NCT06758401 · updated
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Ascension Columbia St. Mary's
- Registry record
- NCT06793215 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Medical College of Wisconsin
- Registry record
- NCT04181060 · updated
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Medical College of Wisconsin
- Registry record
- NCT06890598 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.
Prostate cancer studies recruiting in Milwaukee
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Medical College of Wisconsin ( Site 0020)
- Registry record
- NCT06136624 · updated
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Medical College of Wisconsin · Zablocki Veterans Administration Medical Center
- Registry record
- NCT06931340 · updated
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07200830 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Medical College of Wisconsin ( Site 0008)
- Registry record
- NCT06925737 · updated
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- NRG Oncology
- Study sites
- Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
- Registry record
- NCT05946213 · updated
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Medical College of Wisconsin ( Site 0020)
- Registry record
- NCT06136650 · updated
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Phase 3
- Ages 18 to 100
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Medical College of Wisconsin
- Registry record
- NCT06855277 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.
Melanoma studies recruiting in Milwaukee
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Milwaukee, WI on ClinicalTrials.gov.
Lymphoma studies recruiting in Milwaukee
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Medical College of Wisconsin
- Registry record
- NCT06337318 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Medical College of Wisconsin
- Registry record
- NCT06724237 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Aurora Cancer Care-Milwaukee · Aurora Saint Luke's Medical Center · Aurora Sinai Medical Center
- Registry record
- NCT05675410 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07188558 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Medical College of Wisconsin
- Registry record
- NCT03150693 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Medical College of Wisconsin
- Registry record
- NCT05976763 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Medical College of Wisconsin
- Registry record
- NCT07215910 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Milwaukee, WI on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Milwaukee
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Froedtert Hospital and the Medical College of Wisconsin
- Registry record
- NCT06943755 · updated
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Froedtert Hospital and the Medical College of Wisconsin
- Registry record
- NCT07252232 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Milwaukee, WI on ClinicalTrials.gov.
Ask about studies near Milwaukee
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Wisconsin
All Wisconsin locations
93 studies recruiting across 61 cities.
Madison
46 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections